Racial disparities in clinical trial enrolment

The Lancet

Volumn 372, Issue 9651, 2008, Pages 1713-1714

  Gross, Cary P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; HEALTH CARE ACCESS; HUMAN; PRIORITY JOURNAL; RACISM; RESEARCH SUBJECT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 55749092916     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61714-6     Document Type: Note

References (14)

1. Murthy V.H., Krumholz H.M., and Gross C.P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291 (2004) 2720-2726
2. Mason S., Hussain-Gambles M., Leese B., Atkin K., and Brown J. Representation of South Asian people in randomised clinical trials: analysis of trials' data. BMJ 326 (2003) 1244-1245
3. Newman L.A., Roff N.K., and Weinberg A.D. Cancer clinical trials accrual: missed opportunities to address disparities and missed opportunities to improve outcomes for all. Ann Surg Oncol 15 (2008) 1818-1819
4. Paskett E.D., Reeves K.W., McLaughlin J.M., et al. Recruitment of minority and underserved populations in the United States: the centers for population health and health disparities experience. Contemp Clin Trials (2008) 10.1016/j.cct.2008.07.006 published online July 31.
5. EDICT. Introduction to policy recommendations (2008). http://www.bcm.edu/edict/PDF/EDICT_Project_Policy_Recommendations.pdf (accessed Nov 10, 2008).
6. EDICT. Major deficiencies in the design and funding of clinical trials: a report to the nation improving on how human studies are conducted (2008). http://www.bcm.edu/edict/PDF/EDICT_Project_White_Paper.pdf (accessed Oct 16, 2008).
7. Anon. The unexamined population. Nature Genet 36 (2004) 1
8. Hightower D. Minority participation in clinical trials (Sept 6, 2006). http://www.cancer.gov/newscenter/benchmarks-vol6-issue4 (accessed Oct 16, 2008).
9. Intercultural Cancer Council. Cancer clinical trials: participation by underrepresented populations. http://iccnetwork.org/cancerfacts/ICC-CFS11.pdf (accessed Oct 16, 2008).
10. Kaluzny A., Brawley O., Garson-Angert D., Shaw J., Godley P., and Warnecke R. Assuring access to state-of-the-art care for US minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program. J Natl Cancer Inst 85 (1993) 1945-1950
11. Appelbaum P.S., Roth L.H., Lidz C.W., Benson P., and Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep 17 (1987) 20-24
12. Gross C.P., Krumholz H.M., Van Wye G., Emanuel E.J., and Wendler D. Does random treatment assignment cause harm to research participants?. PLoS Med 3 (2006) e188
13. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
14. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (2006) 1018-1028